All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the pros and cons of bispecific antibodies for multiple myeloma?

Jul 29, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma? 

What are the pros and cons of bispecific antibodies for multiple myeloma?

Mina and Jakubowiak discuss the MajesTEC-1 and MagnetisMM-1 trials, the efficacy and response rates of bispecific antibodies, and the challenges of using bispecific antibodies, such as infection risk. They also compare bispecific antibodies to CAR T-cell therapies and talk about the sequencing of therapies in myeloma treatment.

This educational resource is supported through funds from pharmaceutical companies; a full list of our supporters can be found at https://multiplemyelomahub.com/. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

 

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox